Surveillance colonoscopy following resection of colorectal polyps and cancer

Douglas K Rex MD

Colonic polypectomy is one of the most powerful tools used in clinical medicine. There is really no other organ system where cancer mortality can almost be completely prevented by an examination that does not disturb the anatomy or function of the organ. In nine studies involving more than 3000 patients with colonic adenomas who underwent clearing colonoscopy and then follow-up surveillance (including the National Polyp Study and the Funen Adenoma Follow-up Study), there have been 19 incident colorectal cancers, but only one death from colorectal cancer (1).

POSTPOLYPECTOMY SURVEILLANCE
The principal study that guides postpolypectomy surveillance is the National Polyp Study (2). The National Polyp Study was a randomized, controlled trial in which patients

Key Words:
Adenomas; Colonoscopy; Colorectal cancer; Colorectal polyps

This mini-review was prepared from a presentation made at the American Congress of Gastroenterology, Boston, Massachusetts, October 9 to 14, 1998

Indiana University School of Medicine, Indiana University Hospital, Indianapolis, Indiana, USA

Correspondence and reprints: Dr Douglas K Rex, Indiana University School of Medicine, 550 North University Boulevard, Room 2300, Indianapolis, Indiana 46202, USA. Telephone 317-274-0912, fax 317-2740-0975

Received for publication November 20, 1998. Accepted November 28, 1998
who had undergone clearing colonoscopy were randomly assigned to receive colonoscopy at one year and three years, compared with three years only. Patients with malignant polyps or with sessile adenomas larger than 3 cm were excluded from the study. The primary end point of the study was the occurrence of advanced adenomas at follow-up. An advanced adenoma was defined as one with severe ('high grade') dysplasia or invasive cancer. The principal finding of the study was that the incidence of advanced adenomas was equivalent in the two study arms at 3%. Thus, it was concluded that most patients could have their first follow-up colonoscopy three years after clearing colonoscopy.

It should be noted that the National Polyp Study is very much a miss rate study. Patients in the arm that received two colonoscopies were more likely to have an adenoma detected (42% compared with 32%) and had a total of about 40% more adenomas than the group that had only one colonoscopy. Thus, because the randomization was effective, one can conclude that the miss rate for adenomas in the National Polyp Study was approximately 40%. This miss rate is, in fact, higher than the miss rate for adenomas seen in two tandem colonoscopy studies in which patients underwent colonoscopy twice in the same day (3,4). The inescapable conclusion is that, while colonoscopy has a substantial miss rate for small polyps, including small adenomas, this miss rate has almost no bearing on its effectiveness in reducing mortality from colorectal cancer.

The new colorectal cancer screening benefit for American Medicare beneficiaries includes patients with previous adenomas among those in the 'high risk' group. The Medicare benefit allows payment for colonoscopy at an interval of every two years in patients with previous adenomas or cancer. In fact, essentially all society guidelines had already been changed to recommend three-year intervals after polypectomy or after clearing colonoscopy in cancer patients by the time the Medicare benefit was written. Certainly it is important that clinicians perform colonoscopy in most patients at three-year intervals rather than the two-year intervals that are covered in the American Medicare benefit.

There are situations in which deviation from the three-year interval is clinically appropriate. The most important situation is that of the patient with a large sessile polyp, particularly one that is removed in a piecemeal fashion. As noted above, patients with sessile adenomas larger than 3 cm in size were excluded from the National Polyp Study. In fact, large sessile adenomas are the most dangerous colon polyps encountered in clinical practice. They are more likely to contain invasive cancer, more likely to contain cancer associated with lymph node metastases and more likely to recur after apparent complete endoscopic resection than any other type of colon polyp (5). After apparent complete resection, such polyps should be followed-up at two- to six-month intervals. If there is apparent residual tissue, it should be removed, preferably by snare polypectomy or obliterated by electrocoagulation after biopsy. The recurrence rate after removal of large sessile polyps is 16% to 28%. In addition, a significant number of recurrences can develop one year after complete resection. Therefore, even after apparent complete resection has been verified, it may be best to perform the next colonoscopy in one year.

Another situation in which deviation from the three-year interval is appropriate is a patient with 'numerous' adenomas. In multiple studies, multiplicity of adenomas has been a predictor of advanced adenomas at follow-up. In the National Polyp Study, the most important predictor of an advanced adenoma during follow-up was the presence of three or more adenomas at the index clearing colonoscopy. The guideline published by the Agency for Healthcare Policy and Research (6) states that it is still appropriate to perform a colonoscopy at one year in a patient with 'numerous' adenomas. Obviously, this leaves the definition of 'numerous' up to the clinician's judgment. In my own practice, fewer adenomas would be required to stimulate an examination at one or two years if one or more is larger than 1 cm.

Another potential exception to the three-year rule is the patient with only a single tubular adenoma less than 1 cm in size. The chance that such a patient will have an advanced adenoma at follow-up colonoscopy at three years appears to be less than 1% (2). It would seem reasonable in such patients to expand the interval to five years, although direct observational data from the National Polyp Study, which thus far have only been abstracted (7), show that a family history of colorectal cancer, particularly in a person older than 60 years of age, was another predictor of advanced adenomas at first follow-up. Therefore, it is not my own practice to extend the follow-up interval to five years in patients with single tubular adenomas who also have a family history of colorectal neoplasia, but rather to maintain the interval at three years in those patients.

**POSTCANCER RESECTION**

It should be noted that follow-up of colon cancer is directed toward identifying metachronous lesions. This is particularly true above the rectum, where the anastomotic recurrence rate is only 2% to 3% (1), and most anastomotic recurrences signal intra-abdominal recurrences that are unresectable for cure. The anastomotic recurrence rate in the rectum is around 10% and varies with surgical technique, but still there is no clear evidence that regular follow-up by flexible sigmoidoscopy can improve the survival rate. Additional study is needed to determine whether regular examination that includes endoscopic ultrasound can increase the identification of surgically curable rectal recurrences. The most important examination for patients with colon cancer is the colonoscopy that clears the colon of synchronous disease. If this cannot be performed preoperatively because of obstruction, it should be performed two to three months after surgery, even if a preoperative barium enema revealed no synchronous disease proximal to the tumour. Once the colon has been cleared, repeating colonoscopy at three- to five-year intervals is adequate (8), or according to the associated adenoma findings. An exception is patients with hereditary nonpolyposis colorectal
cancer, who should be treated with subtotal colectomy followed by annual endoscopy of the rectum for the remainder of their lives.

REFERENCES
Submit your manuscripts at http://www.hindawi.com